Undervaluation of arthralgies: role of nurses in early immunotoxicity detection

Authors

Catarina Almeida Instituto Português de Oncologia de Lisboa, Unidade de Técnicas de Pneumologia, Lisboa
Raquel Chemela Instituto Português de Oncologia de Lisboa, Lisboa

Keywords:

Immunotherapy, checkpoint inhibitors, immune-related adverse events, rheumatic and musculoskeletal diseases, arthralgias

Abstract

The use of immune checkpoint inhibition (ICI) has revolutionized cancer treatment. However, these medications are associated with significant and potentially debilitating immune-related adverse events or even life threathing. While the majority of toxicities have been well studied, rheumatic complications have been less widely recognized and characterized. We describe a case study in which both performance status and quality of life of a patient where affected by rheumatological toxicity as wells the nurses’ role in the early recognition and toxicity’ management in order to enhance the patient’ quality of life.

Downloads

Download data is not yet available.

References

Abdel-Wahab, N., Suarez-Almazor, M.E. (2019). Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy. Rheumatology, 58, vii40–vii48.

Aranda S, Jefford, M., Yates P, et al (2012). Impact of a novel nurse-led prechemotherapy education intervention (ChemoEd) on patient distress, symptom burden, and treatment-related information and support needs: results from a randomised, controlled trial. Ann OncoL, Jan 23(1):222-231.

Benfaremo, D., Manfredi, L., Luchetti, M.M. et al (2018). Musculoskeletal and Rheumatic Diseases Induced by Immune Checkpoint Inhibitors: A Review of the Literature. Curr Drug Saf. 13(3):150-164.

Brahmer, J.R., Lacchetti, C., Schneider, B.J. et al (2018). Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology(ASCO) clinical practice guideline. J Clin Oncol, 36:1714–68.

British Geriatrics Society (2017). Fit for Frailty - Consensus best practice guidance for the care of older people living in community and outpatient settings. London, 22p.

Broens, T.H; Huis IN’T Veld, RM; Vollenbroek-Hutten, MM et al (2007). Determinants of successful telemedicine implementations: a literature study. J Telemed Telecare 13(6):303-9.

Butcher, HK; Bulechek , GM; Dochterman, J.M.M., et al (2018). Nursing Interventions Classification (NIC). Elsevier Health Sciences, 7ª edição. 512 pg.

Cappelli, L.C., Gutierrez, A.K., Bingham, C.O., et al (2017). Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature. Arthritis Care Res, 69:1751_63.

Champiat, S., Lambotte, O., Barreau, et al (2016). Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol, Apr 27(4):559–74.

Elias, R., Morales, J., Presley, C. (2017). Checkpoint Inhibitors for Non-Small Cell Lung CancerAmong Older Adults. Curr Oncol Rep19:62.

Fabião, A. (2004) Pessoa com doença oncológica: Re(encontro com a qualidade de vida – Instituto de Ciencias Biomedicas de Abel Salazar, Universidade do Porto.

Haanen, J.B.A.G., Carbonnel, F., Robert, C. et al (2017); ESMO Guidelines Committee. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol;28 Suppl 4:iv119–42.

Henderson, V. (2007) Princípios básicos de enfermagem da CIE, 1ª ed., Lusodidacta, Portugal, 92p.

Hurria, A., Mohile, S., Gajra, A. et al. (2016). Validation of a prediction tool for chemotherapy toxicity in older adults with cancer. J Clin Oncol;34:2366–U104.

Jamal, S., Hudson, M., Fifi-Mah, A. et al (2020) Immune-related Adverse Events Associated with Cancer Immunotherapy: A Review for the Practicing Rheumatologist. J Rheumatol, February, 47 (2) 166-175.

Mcilfatrick, S., Sullivan, K., Mckenna, H. et al (2007). Patients’ experiences of having chemotherapy in a day hospital setting. J Adv Nurs 59(3):264-73.

Mellisaropoulos, K., Klavdianou, K., Filippopoulou, A. et al (2020) - Rheumatic Manifestations in Patients Treated with Immune Checkpoint Inhibitors Int J Mol Sci. 21(9):3389.

Mooradian, M.J., Nasrallah, M., Gainor, J.F. et al (2018) Musculoskeletal rheumatic complications of immune checkpoint inhibitor therapy: a single center experience. Semin Arthritis Rheum 48(6):1127-1132.

Noronha, V., Sekhar, A., Vijay, M. et al. (2020). Systemic therapy for limited stage small cell lung carcinoma. J Thorac Dis;12(10):6275-6290.

Paredes, T., Simões, M.R., Canavarro, M.C. et al (2008) - Impacto da Doença Cronica na Qualidade de Vida: comparação entre indivíduos da população geral e doente com tumor no aparelho locomotor. Psicologia, Saúde e Doença, 9 (1), 73-87.

Postow, M.A., Sidlow, R., Hellmann, M.D. (2018). Immunerelated adverse events associated with immune checkpoint blockade. N Engl J Med, 378:158–68.

Steven, N. M. & Fisher, B. A. (2019) - Management of rheumatic complications of immune checkpoint inhibitor therapy – an oncological perspective Rheumatology 2019;58:vii29–vii39.

US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) version 5.0., 2017.

Wang, P., Chen, Y., Songs, S. Y. et al. (2017 ). Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis. JAMA Oncology.18; 8:730.

Downloads

PDF (Português (Portugal))

Published

2021-06-07

How to Cite

Almeida C, Chemela R. Undervaluation of arthralgies: role of nurses in early immunotoxicity detection. Onco.News [Internet]. 2021 Jun. 7 [cited 2024 Nov. 26];(42):56-62. Available from: https://onco.news/index.php/journal/article/view/21